Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients

Abstract

Background Anaplastic lymphoma kinase (ALK) fusion events account for 3 to 7% of genetic alterations in patients with nonsmall cell lung cancer (NSCLC). This study aimed to explore the landscape of ALK fusion-positive and ALK fusion-negative in a large cohort of NSCLC patients.
Methods The formalin-fixed paraffin-embedded specimens of NSCLC patients who underwent next-generation sequencing from 2020 to 2023 in Yinfeng Gene Technology Co., Ltd. Clinical laboratory were included in this study.
Results In the current study, a total of 180 (3.20%) patients tested positive for ALK fusions in 5,622 NSCLC samples. Within the ALK-positive cohort, a total of 228 ALK fusions were identified. Furthermore, five novel ALK fusion partners, including DAB1-ALK, KCMF1-ALK, KIF13A-ALK, LOC643770-ALK, and XDH-ALK were identified. In cases with ALK fusion-positive, TP53 alterations were the most prevalent (26.3%), followed by CDKN2A (8.4%), epidermal growth factor receptor (EGFR, 5.6%), and ALK (5.6%). By contrast, EGFR alterations were most prevalent (51%) in patients with ALK fusion-negative NSCLC, followed by TP53 (42.7%), KRAS (11.6%), and CDKN2A (11.3%). A total of 10 cases where ALK fusion co-occurred with EGFR mutations were also identified. Notably, the ALK fusion positivity rate was higher in younger patients (p < 0.0001) and in female patients (p = 0.0429). Additionally, positive ALK test results were more prevalent in patients with high programmed death-ligand 1 expression, especially when applying a 50% cutoff.
Conclusions Collectively, these findings offer valuable genomic insights that could inform the personalized clinical care of patients with NSCLC harboring ALK fusions within the context of precision medicine.

Keywords

NSCLC / ALK fusion / next-generation sequencing / genomic landscape

References

[[1]] Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA.Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83(05) 584-594

[[2]] de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res 2018; 7(03) 220-233

[[3]] Soda M, Choi YL, Enomoto M.et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153): 561-566

[[4]] Solomon B, Varella-Garcia M, Camidge DR.ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009; 4(12) 1450-1454

[[5]] Hallberg B, Palmer RH.Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013; 13(10) 685-700

[[6]] He Y, Sun LY, Gong R.et al.The prevalence of EML4-ALK variants in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Biomarkers Med 2019; 13(12) 1035-1044

[[7]] Takeuchi K, Choi YL, Togashi Y.et al.KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15(09) 3143-3149

[[8]] Rikova K, Guo A, Zeng Q.et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131(06) 1190-1203

[[9]] Togashi Y, Soda M, Sakata S.et al.KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012; 7(02) e31323

[[10]] Feng T, Chen Z, Gu J, Wang Y, Zhang J, Min L.The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma. Lung Cancer 2019; 137: 19-22

[[11]] Rodig SJ, Shapiro GI.Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 2010; 11(12) 1477-1490

[[12]] Markham A.Brigatinib: first global approval. Drugs 2017; 77(10) 1131-1135

[[13]] Kuang S, Leighl NB.Lorlatinib in ALK-rearranged lung cancer. Cancer Cell 2021; 39(01) 25-27

[[14]] Li W, Liu Y, Li W, Chen L, Ying J.Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC. J Thorac Oncol 2020; 15(07) 1223-1231

[[15]] Kang J, Zhang XC, Chen HJ.et al.Complex ALK fusions are associated with better prognosis in advanced non-small cell lung cancer. Front Oncol 2020; 10: 596937

[[16]] Zhao R, Zhang J, Han Y.et al.Clinicopathological features of ALK expression in 9889 cases of non-small-cell lung cancer and genomic rearrangements identified by capture-based next-generation sequencing: a Chinese retrospective analysis. Mol Diagn Ther 2019; 23(03) 395-405

[[17]] Ke L, Xu M, Jiang X, Sun X.Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase/oncogene or c-ros oncogene 1 (ALK/ROS1) fusions inflict non-small cell lung cancer (NSCLC) female patients older than 60 years of age. Med Sci Monit 2018; 24(24) 9364-9369

[[18]] Ota K, Azuma K, Kawahara A.et al.Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res 2015; 21(17) 4014-4021

[[19]] Chen WS, Bindra RS, Mo A.et al.CDKN2A copy number loss is an independent prognostic factor in HPV-negative head and neck squamous cell carcinoma. Front Oncol 2018; 8: 95

[[20]] Yin J, Li Y, Zhao H.et al.Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population. Cancer Med 2016; 5(09) 2171-2179

[[21]] Sawada R, Maehara R, Oshikiri T.et al.MDM2 copy number increase: a poor prognostic, molecular event in esophageal squamous cell carcinoma. Hum Pathol 2019; 89: 1-9

[[22]] Huang F, Chang H, Greer A.et al.IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines. Mol Cancer Ther 2015; 14(02) 620-630

[[23]] Gainor JF, Varghese AM, Ou SH.et al.ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013; 19(15) 4273-4281

[[24]] Li Y, Li Y, Yang T.et al.Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One 2013; 8(01) e52093

[[25]] Popat S, Vieira de Araújo A, Min T. et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011; 6(11) 1962-1963

[[26]] Tiseo M, Gelsomino F, Boggiani D.et al.EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011; 71(02) 241-243

[[27]] Marusyk A, Almendro V, Polyak K.Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer 2012; 12(05) 323-334

[[28]] Ulivi P, Puccetti M, Capelli L.et al.Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue. J Clin Pathol 2013; 66(08) 708-710

[[29]] Yang JJ, Zhang XC, Su J.et al.Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 2014; 20(05) 1383-1392

[[30]] Imamura F, Inoue T, Kimura M, Nishino K, Kumagai T.A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation. Respir Med Case Rep 2016; 19: 137-139

[[31]] Christopoulos P, Kirchner M, Bozorgmehr F.et al.Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma. Int J Cancer 2019; 144(01) 190-199

[[32]] Yoneshima Y, Ijichi K, Anai S.et al.PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer 2018; 118: 36-40

[[33]] Kim SJ, Kim S, Kim DW.et al.Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer. Cancer Res Treat 2019; 51(03) 1231-1240

[[34]] Yang CY, Liao WY, Ho CC.et al.Association of programmed death-ligand 1 expression with fusion variants and clinical outcomes in patients with anaplastic lymphoma kinase-positive lung adenocarcinoma receiving crizotinib. Oncologist 2020; 25(08) 702-711

[[35]] Li M, Hou X, Chen J.et al.ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). Lung Cancer 2022; 165: 54-62

[[36]] Zhou Y, Song L, Xu Q.et al.Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib. Lung Cancer 2022; 167: 58-64

[[37]] Chang GC, Yang TY, Chen KC.et al.ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci Rep 2020; 10(01) 21063

[[38]] Tian X, Li Y, Huang Q, Zeng H, Wei Q, Tian P.High PD-L1 expression correlates with an immunosuppressive tumour immune microenvironment and worse prognosis in ALK-rearranged non-small cell lung cancer. Biomolecules 2023; 13(06) 991

RIGHTS & PERMISSIONS

2024 Global Medical Genetics